Vyome to Present Full Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026
Vyome Holdings, Inc. , a clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory and rare conditions, has announced that it will present comprehensive Phase 2 clinical data for its investigational therapy, VT-1953, at the American Association for Cancer Research (AACR) Annual Meeting 2026. The conference is scheduled to take place from April 17 to April 22, 2026, in San Diego, California.
The presentation will include detailed findings from an investigator-initiated Phase 2 clinical study evaluating the efficacy and safety of VT-1953 topical gel in patients suffering from malignant fungating wounds (MFW)—a severe and often distressing complication seen in advanced cancer patients.
Addressing a Significant Unmet Medical Need
Malignant fungating wounds are a rare but debilitating condition, affecting approximately 10% of patients with advanced-stage cancers. These wounds occur when cancerous tumors invade the skin and underlying tissues, leading to ulceration, necrosis, and infection. Among the most distressing symptoms associated with MFW is malodor, which can significantly impair a patient’s quality of life, causing social isolation, emotional distress, and reduced dignity.
Despite the seriousness of the condition, there are currently no FDA-approved therapies specifically indicated to treat malodor and other symptoms associated with MFW. Existing treatments are largely palliative and often provide limited or inconsistent relief.
Vyome’s investigational drug VT-1953 aims to fill this critical therapeutic gap by offering a targeted, mechanism-based treatment approach.
Overview of VT-1953 and Its Mechanism of Action
VT-1953 is described as a first-in-class topical therapy designed to address both the microbial and inflammatory components of malignant fungating wounds.
The drug operates through a dual mechanism of action:
- Inhibition of DNA Gyrase (DNA Gyr):
This mechanism targets bacterial replication, helping to control infection and reduce microbial load, which is a key contributor to wound malodor. - Modulation of MD2/TLR Interactions:
VT-1953 also acts on inflammatory signaling pathways by modulating MD2/TLR (Toll-like receptor) interactions. This helps reduce inflammation, which plays a central role in wound progression and symptom severity.
By combining antimicrobial and anti-inflammatory effects, VT-1953 aims to deliver comprehensive symptom relief for patients with MFW.
Key Highlights of the Phase 2 Study
The Phase 2 clinical trial evaluated the safety, tolerability, and efficacy of VT-1953 topical gel compared to a vehicle (placebo) treatment in patients with malodorous malignant fungating wounds.
Study Design
- Type: Investigator-initiated Phase 2 clinical study
- Population: Patients with advanced cancer experiencing MFW-related malodor
- Intervention: VT-1953 topical gel vs. vehicle control
- Endpoints:
- Reduction in malodor
- Improvement in wound-related symptoms
- Safety and tolerability profile
Clinical Findings
Vyome reported that the study generated promising clinical outcomes, demonstrating:
- Noticeable reduction in malodor in patients treated with VT-1953 compared to control
- Improvement in associated symptoms, potentially including inflammation, exudate, and discomfort
- Favorable safety and tolerability profile, with no major safety concerns reported
Additionally, the results were supported by strong mechanistic insights, reinforcing the scientific rationale behind the drug’s dual-action approach.
Presentation Details at AACR 2026
The full dataset and supporting preclinical findings will be presented during a dedicated session at AACR 2026.
- Event: American Association for Cancer Research Annual Meeting 2026
- Location: San Diego, California
- Date & Time: April 21, 2026 | 9:00 AM – 12:00 PM
- Session Title: Phase II and Phase III Clinical Trials in Progress
- Presentation Number: CT208 / 3
- Presentation Title: Final results from a Phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wounds
Authors of the Study
The study is authored by:
- Arshit Narang, MBBS
- Prashant Prakash Lad, MD
- Shiladitya Sengupta, PhD
Leadership Commentary on the Results
Vyome’s leadership emphasized both the clinical importance and commercial potential of VT-1953.
Venkat Nelabhotla, CEO of Vyome, highlighted the unmet need in this space, stating that there are currently no approved therapies addressing malodor in MFW patients. He also noted that the company plans to initiate interactions with the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 to discuss the design of a pivotal clinical study.
He further pointed to the significant market opportunity, citing third-party estimates that place the total addressable U.S. market at approxiately $2.2 billion.
Nelabhotla also underscored the broader relevance of the drug’s mechanism, noting that inflammation remains one of the most pervasiv and challenging problems in global healthcare.
Scientific Perspective and Future Development
Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Co-founder of Vyome, expressed enthusiasm about the study’s acceptance at AACR, describing it as recognition of the scientific strength and clinical relevance of the data.
He emphasized that the combination of promising clinical outcomes and strong mechanistic alignment supports the advancement of VT-1953 into pivotal trials, which will be critical for regulatory approval.
Market Opportunity and Strategic Outlook
The development of VT-1953 represents not only a clinical breakthrough opportunity but also a significant commercial prospect.
Key Market Drivers
- Lack of approved therapies for MFW-related symptoms
- Growing population of advanced cancer patients
- Increasing focus on quality of life and palliative care
- High unmet need in oncology supportive care
With an estimated $2.2 billion U.S. market opportunity, VT-1953 has the potential to become a first-in-class, standard-of-care therapy if future trials confirm its efficacy and safety.
Next Steps: Regulatory and Clinical Pathway
Following the Phase 2 results, Vyome plans to:
- Engage with the FDA in Q2 2026 to define the pathway for pivotal trials
- Design and initiate Phase 3 (pivotal) studies
- Continue generating supportive preclinical and mechanistic data
- Expand clinical understanding of VT-1953 across related inflammatory conditions
These steps will be critical in moving the drug toward regulatory approval and commercialization.
The upcoming presentation of VT-1953 Phase 2 data at AACR 2026 marks an important milestone for Vyome Holdings and for patients suffering from malignant fungating wounds. With its innovative dual mechanism of action, encouraging clinical results, and strong scientific foundation, VT-1953 has the potential to address a long-standing unmet need in oncology supportive care.
If successful in future trials, this therapy could significantly improve the quality of life for patients with advanced cancer, offering relief from one of the most distressing symptoms associated with malignant wounds.
About Vyome Holdings, Inc.
Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook”, and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome’s business strategy, the timing and subject of our AACR presentation, and our interactions with the FDA. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding Vyome’s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome’s ability to leverage the India innovation corridor and otherwise advance VT-1953 into clinical development in a capital-efficient manner; Vyome’s ability to raise capital to fund continuing operations; our ability to protect Vyome’s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; Vyome’s ability to complete capital raising transactions; and other factors relating to Vyome’s industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Vyome’s assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.
